DDIT3 and lymphoma: Currently, a phase 2/3 trial of venetoclax plus R-CHOP or DA-EPOCH-R vs R-CHOP or DA-EPOCH-R alone in patients with DLBCL or high-grade B-NHL with translocations of BCL2 and MYC genes (double-hit lymphomas) or dual expression of BCL-2 and MYC proteins (double expressing lymphoma) is ongoing (NCT03984448).